Cargando…
Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors
Patients with autoimmune rheumatic diseases (ARD) have an increased risk for tuberculosis (TB). The use of tumor necrosis factor inhibitors (TNFi) and glucocorticoids in these patients has been associated with an increased prevalence of latent TB reactivation. Over the last few years, several biolog...
Autores principales: | Evangelatos, Gerasimos, Koulouri, Vasiliki, Iliopoulos, Alexios, Fragoulis, George E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309385/ https://www.ncbi.nlm.nih.gov/pubmed/32612710 http://dx.doi.org/10.1177/1759720X20930116 |
Ejemplares similares
-
Hidradenitis suppurativa: infection, autoimmunity, or both?
por: Constantinou, Costas A, et al.
Publicado: (2019) -
Factors associated with sepsis risk in immune-mediated inflammatory
diseases receiving tumor necrosis factor inhibitors: a nationwide
study
por: Chao, Wen-Cheng, et al.
Publicado: (2020) -
JAK inhibitors and infections risk: focus on herpes
zoster
por: Sunzini, Flavia, et al.
Publicado: (2020) -
Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review
por: Tsai, Y. C., et al.
Publicado: (2020) -
Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations
por: Koutsianas, Christos, et al.
Publicado: (2020)